Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The new chart & the 450 days duration % numbers.

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 29, 2023 12:57pm

210 Views

Post# 35420878

RE:RE:The new chart & the 450 days duration % numbers.

The new format is fine, but it doesn't provide the durable complete response for the entire evaluated population of the trial and this is the first thing I look for when results come out.

Durable response is the secondary objective and it's an important way to compare our efficacy with already approved treatments. Keytruda finished with 19% and Adstiladrin with 24% On Nov 29 our 450 day CR rate for all treated patients was 28% What is it now?

I'm hoping in the future we continue to get data in both the new format and also the overall response rates.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale